Drug Efficacy Studies in NASH Mouse Model_ Mesenchymal stem/stromal cell small extracellular vesicles
Today’s topic is Effective cell therapy and exosome for NASH treatment. I would like to introduce a study published by our client, Agency for Science, Technology and Research (A*STAR) (SGP), in which they used our pre-clinical services in our proprietary NASH model called STAM™.
Title: MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH, (Zhang et al., Int J Mol Sci., 2023)
In this study, the efficacy of mesenchymal stromal cell/stem cell small extracellular vesicles (MSC-sEV) in the treatment of NASH is being evaluated. Authors show that compared to STAM™ mice in the vehicle-treated group, NASH-phase STAM™ mice treated with MSC-sEV had significantly lower NAFLD activity score (the main clinical endpoint for evaluating fatty liver) and fibrosis area in the liver. These Results suggest that MSC-sEV may be useful in the treatment of NASH.
The STAM™ mouse is the world’s first pathological mouse model to show the progression of NASH to liver cancer, and was developed here at SMC Laboratories. This model shows a similar pathology to human NASH (steatosis – NASH – liver fibrosis – HCC). Therefore, the STAM™ model has been used in many efficacy studies, as well as in basic research.